alpha-aminopyridine has been researched along with Follicular Thyroid Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benisvy, D; Borson-Chazot, F; Bournaud, C; Dantony, E; de la Fouchardière, C; Decaussin-Petrucci, M; Delahaye, A; Do Cao, C; Eberle, MC; Illouz, F; Klein, M; Lapras, V; Lasolle, H; Leboulleux, S; Lopez, J; Niccoli, P; Rabilloud, M; Schlumberger, M; Tabarin, A; Wassermann, J | 1 |
1 trial(s) available for alpha-aminopyridine and Follicular Thyroid Carcinoma
| Article | Year |
|---|---|
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pilot Projects; Progression-Free Survival; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2018 |